23
THE NEW APPROACH

THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Embed Size (px)

Citation preview

Page 1: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

THE NEW APPROACH

Page 2: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Introduction

For a long period of time it was state of the art to design drugs displaying one definedpharmacological mode of action.

These drugs failed in the approach to curecomplex diseases!

Recently the medical community postulated the need for drugs displaying a mode of action resulting in pleiotropic effects for treatment of complex diseases like CNS injury or neurodegeneration.

Page 3: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Introduction

The mature central nervous system has limited capacity for self-

renewal and repair after injury or neurodegeneration, therefore

therapeutic strategies with effects similar to neurotrophic factors

resulting in pleiotropic effects are required.

Cerebrolysin acts similar to neurotrophic factors and is

therefore an optimal treatment strategy after CNS injury or

neurodegeneration.

Page 4: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin

NEUROTROPHIC MECHANISM

neur

onal

sur

viva

l

neur

opro

tect

ion

neur

opla

stic

ity

neur

ogen

esis

Page 5: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Indications

DEMENTIASTROKE

TBI

Page 6: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Protein powder

Cerebrolysin Concentrate

Starting material

Active Pharmaceutical Ingredient

Enzymatic hydrolysis

Molecular weight cut-off filtration

Addition of amino acids

Ethanol precipitation

Cerebrolysin – Characterisation

Page 7: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Mode of action

Cerebrolysin, a balanced peptide preparation acting

like neurotrophic factors.

 

General Pharmacodynamics (PD)

Special Pharmacodynamics (PD)

Page 8: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

The neurotrophic mechanism of Cerebrolysin results in

pleiotropic effects:

• neuronal survival

• neuroprotection

• neuroplasticity

• neurogenesis

Cerebrolysin – General PD

Page 9: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Neuronal survival

Neurotrophic factors exert survival-promoting and trophic actions on neuronal cells to avoid neuronal atrophy, hypofunction and cell death.             

Page 10: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Neuroprotection

Neurotrophic factors limit neuronal dysfunction and attempt to maintain the highest possible integrity of cellular interactions in the brain under detrimental conditions.

Page 11: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Neuroplasticity

Neurotrophic factors enable neuroplasticity, a process which allows the brain to adapt by "re-wiring" in response to changes in the environment and which allows the regrowth of damaged neuronal processes.

Page 12: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Neurogenesis

Neurotrophic factors induce differentiation of progenitor cells to form neurons, which become functionally integrated into the surrounding brain tissue during pre-natal development but also throughout adulthood.

Page 13: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Page 14: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – General PD

Page 15: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Special PD

Efficacy of Cerebrolysin has been proven in several in-

vitro and in-vivo experiments with model systems for

• Dementia

• Stroke

• TBI

Page 16: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Special PD

Model systems for diseases:

DEMENTIA

STROKE

TBI

Page 17: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Special PD

Findings in Dementia Models:

- Cerebrolysin decreases A deposition by regulating APP maturation.

- Cerebrolysin acts as a synaptic modulator to promote integrity of neuronal

circuits.

- Cerebrolysin restores neuronal cytoarchitecture resulting in improved

behavioral performance.

- Cerebrolysin stimulates neurogenesis in the dendate gyrus, which might

provide a basis for neuronal replacement therapy in neurodegenerative

diseases.

Page 18: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Special PD

Findings in Stroke Models:

- Cerebrolysin stabilizes cytoskeleton by inhibition of calpain.

- Cerebrolysin stimulates neurogenesis to promote integrity of neuronal

circuits, a potential mechanisms for self-repair after stroke.

- Cerebrolysin decreases infarct volume.

- Cerebrolysin limits edema formation.

- Cerebrolysin promotes functional recovery.

Page 19: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Special PD

Findings in TBI Models:

- Cerebrolysin prevents apoptosis of lesioned motoneurons.

- Cerebrolysin promotes functional recovery.

Page 20: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin – Summary

Cerebrolysin, a balanced peptide preparation acting like

neurotrophic factors.

Page 21: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

The neurotrophic mechanism of Cerebrolysin results in

pleiotropic effects:

• neuronal survival

• neuroprotection

• neuroplasticity

• neurogenesis

Cerebrolysin – Summary

Page 22: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Efficacy of Cerebrolysin has been proven in several in-

vitro and in-vivo experiments with model systems for

• Dementia

• Stroke

• TBI

Cerebrolysin – Summary

Page 23: THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action

Cerebrolysin is an optimal treatment strategy after

CNS injury or neurodegeneration.

Cerebrolysin – Conclusion